Table 1.
Participation in cancer screening programs in Japan during fiscal year (FY) 2017–2020 (percentages in parentheses).
| FY 2017–2019, avg. | FY 2020 | Percentage change | |||||
|---|---|---|---|---|---|---|---|
| Gastric cancer (UGI or Endoscopy) | |||||||
| Total | 3,837,143 | 2,837,083 | -26.1 | ||||
| Sex | Male | 1,678,154 | (43.7) | 1,263,891 | (44.5) | -24.7 | |
| Female | 2,158,989 | (56.3) | 1,573,192 | (55.5) | -27.1 | ||
| Age, y | 40–49 | 411,252 | (10.7) | 280,183 | (9.9) | -31.9 | |
| 50–59 | 539,951 | (14.1) | 423,897 | (14.9) | -21.5 | ||
| 60–69 | 1,217,547 | (31.7) | 814,228 | (28.7) | -33.1 | ||
| 70–79 | 1,327,201 | (34.6) | 1,046,644 | (36.9) | -21.1 | ||
| 80- | 341,191 | (8.9) | 272,131 | (9.6) | -20.2 | ||
| Type of screening | Mass screening | 2,143,680 | (55.9) | 1,412,663 | (49.8) | -34.1 | |
| Individual screening | 1,693,463 | (44.1) | 1,424,420 | (50.2) | -15.9 | ||
| Gastric cancer (UGI) | |||||||
| Total | 2,819,623 | 1,910,660 | -32.2 | ||||
| Sex | Male | 1,248,063 | (44.3) | 863,923 | (45.2) | -30.8 | |
| Female | 1,571,561 | (55.7) | 1,046,737 | (54.8) | -33.4 | ||
| Age, y | 40–49 | 411,252 | (14.6) | 280,183 | (14.7) | -31.9 | |
| 50–59 | 392,302 | (13.9) | 273,295 | (14.3) | -30.3 | ||
| 60–69 | 895,957 | (31.8) | 549,058 | (28.7) | -38.7 | ||
| 70–79 | 910,524 | (32.3) | 659,832 | (34.5) | -27.5 | ||
| 80- | 209,588 | (7.4) | 148,292 | (7.8) | -29.2 | ||
| Type of screening | Mass screening | 2,125,243 | (75.4) | 1,396,841 | (73.1) | -34.3 | |
| Individual screening | 694,380 | (24.6) | 513,819 | (26.9) | -26.0 | ||
| Gastric cancer (Endoscopy) | |||||||
| Total | 1,017,519 | 926,423 | -9.0 | ||||
| Sex | Male | 430,091 | (42.3) | 399,968 | (43.2) | -7.0 | |
| Female | 587,428 | (57.7) | 526,455 | (56.8) | -10.4 | ||
| Age, y | 50–59 | 147,649 | (14.5) | 150,602 | (16.3) | 2.0 | |
| 60–69 | 321,590 | (31.6) | 265,170 | (28.6) | -17.5 | ||
| 70–79 | 416,677 | (41.0) | 386,812 | (41.8) | -7.2 | ||
| 80- | 131,603 | (12.9) | 123,839 | (13.4) | -5.9 | ||
| Type of screening | Mass screening | 18,437 | (1.8) | 15,822 | (1.7) | -14.2 | |
| Individual screening | 999,082 | (98.2) | 910,601 | (98.3) | -8.9 | ||
| Colorectal cancer (FOBT) | |||||||
| Total | 8,424,776 | 7,298,673 | -13.4 | ||||
| Sex | Male | 3,321,617 | (39.4) | 2,893,898 | (39.6) | -12.9 | |
| Female | 5,103,159 | (60.6) | 4,404,775 | (60.4) | -13.7 | ||
| Age, y | 40–49 | 856,762 | (10.2) | 693,443 | (9.5) | -19.1 | |
| 50–59 | 953,545 | (11.3) | 816,647 | (11.2) | -14.4 | ||
| 60–69 | 2,368,211 | (28.1) | 1,802,854 | (24.7) | -23.9 | ||
| 70–79 | 3,086,488 | (36.6) | 2,874,921 | (39.4) | -6.9 | ||
| 80- | 1,159,770 | (13.8) | 1,110,808 | (15.2) | -4.2 | ||
| Type of screening | Mass screening | 3,569,051 | (42.4) | 2,787,198 | (38.2) | -21.9 | |
| Individual screening | 4,855,726 | (57.6) | 4,511,475 | (61.8) | -7.1 | ||
| Lung cancer (Chest X-ray) | |||||||
| Total | 7,918,697 | 6,593,528 | -16.7 | ||||
| Sex | Male | 3,198,703 | (40.4) | 2,679,184 | (40.6) | -16.2 | |
| Female | 4,719,994 | (59.6) | 3,914,344 | (59.4) | -17.1 | ||
| Age, y | 40–49 | 710,592 | (9.0) | 556,306 | (8.4) | -21.7 | |
| 50–59 | 778,708 | (9.8) | 639,820 | (9.7) | -17.8 | ||
| 60–69 | 2,189,666 | (27.7) | 1,571,519 | (23.8) | -28.2 | ||
| 70–79 | 3,010,602 | (38.0) | 2,684,477 | (40.7) | -10.8 | ||
| 80- | 1,229,129 | (15.5) | 1,141,406 | (17.3) | -7.1 | ||
| Type of screening | Mass screening | 4,409,525 | (55.7) | 3,163,019 | (48.0) | -28.3 | |
| Individual screening | 3,509,172 | (44.3) | 3,430,509 | (52.0) | -2.2 | ||
| Breast cancer (Mammography) | |||||||
| Total | 3,100,533 | 2,565,900 | -17.2 | ||||
| Age, y | 40–49 | 879,936 | (28.4) | 727,345 | (28.3) | -17.3 | |
| 50–59 | 681,034 | (22.0) | 586,869 | (22.9) | -13.8 | ||
| 60–69 | 835,959 | (27.0) | 633,753 | (24.7) | -24.2 | ||
| 70–79 | 607,644 | (19.6) | 530,876 | (20.7) | -12.6 | ||
| 80- | 95,960 | (3.1) | 87,057 | (3.4) | -9.3 | ||
| Type of screening | Mass screening | 1,495,147 | (48.2) | 1,105,214 | (43.1) | -26.1 | |
| Individual screening | 1,605,385 | (51.8) | 1,460,686 | (56.9) | -9.0 | ||
| Cervical cancer (Pap smear) | |||||||
| Total | 4,260,272 | 3,767,370 | -11.6 | ||||
| Age, y | 20–29 | 380,885 | (8.9) | 397,995 | (10.6) | 4.5 | |
| 30–39 | 781,530 | (18.3) | 702,443 | (18.6) | -10.1 | ||
| 40–49 | 939,360 | (22.0) | 831,412 | (22.1) | -11.5 | ||
| 50–59 | 722,492 | (17.0) | 655,134 | (17.4) | -9.3 | ||
| 60–69 | 800,719 | (18.8) | 618,666 | (16.4) | -22.7 | ||
| 70–79 | 551,198 | (12.9) | 484,993 | (12.9) | -12.0 | ||
| 80- | 84,088 | (2.0) | 76,727 | (2.0) | -8.8 | ||
| Type of screening | Mass screening | 1,195,295 | (28.1) | 856,012 | (22.7) | -28.4 | |
| Individual screening | 3,064,977 | (71.9) | 2,911,358 | (77.3) | -5.0 | ||